Techinvention focused on developing new biologics for infectious diseases that are affordable in developing nations

TechInvention is focused on the development of innovative biologics that are affordable for developing countries for infectious diseases using Recombinant Technology to develop platform technologies for ecombinant vaccines, Phage Display technology based Recombinant Monoclonal Antibodies, and Recombinant Endolysins as Enzybiotics for antimicrobial resistance management.

Recombinant technology involves the production of a desired antigen in an expression system without its infectious factors/ virulence factors. They elicit an immune response strong enough to confer immunity without causing severe infection. The technology has a range of advantages compared to other classic vaccines on the market. Recombinant technology makes it easy to mass produce antigens for vaccine production for safer and more efficacious vaccines, making it a more economically viable option as well. The profitability varies based on the vaccine in question. Overall, because of its high yields, commercial viability, and affordability, the technology has been widely explored for modern vaccine manufacture, making it one of the primary approaches for the COVID-19 vaccine.

TechInvention is one of the few companies that made it to the finale of National Startup Awards 2021 and also got to be a part of the team that presented policy suggestions to the Hon’ble Prime Minister Narendra Modi recently on the theme “Nudging the DNA” as part of a DPIIT, Startup India, and Invest India programme in conjunction with Startup Innovation Week. It’s platform technologies focused on infectious diseases majorly impacting the developing world are positioned to play a vital role in pandemic preparedness and capacity building.

 Techinvention, amongst other deals, has successfully enabled a tech transfer deal of Haemophilus influenza B vaccine technology to a middle-income country and Hepaitis B vaccine to a least developed country. While a country’s authoritative body sets immunization schedules, the The hepatitis A immunization program consists of two doses, the first given at 6 months of age and the second at 6 months to 1 year. The hepatitis A vaccine is not officially included in the National Public Immunization Program but is available on the private market. Techinvention is working towards strengthening its R&D Portfolio as it currently works on a biantigent COVID-19 Vaccines to handle Variants of Concern.

Techinvention currently supports clinical trials of five different products from four other companies amongst which is direct deal with Eubiologics Co, South Korea, to bring EuvicholPlus, the first oral cholera vaccine (OCV), in a single-dose, low-density polyethylene package to India. Eubiologics has shipped more than 55 million doses to UN health authorities.

TechInvention proves to be an emerging SME in the healthcare sector by winning the 21st edition of SME awards in 2022″ with its plans to enable “greater health equity for all” globally. “It is a great honor to receive this SME Award in 2022, as our entire team is committed to achieving this mission of ensuring global health, as stated by Dr. Syed Ahmed, Founder of Techinvention.

Although TechInvention is a bootstrapped startup, it have been cash positive since year two of inception and fund all of their research and development projects from internal accruals. Techinvention is getting into a JV with a large manufacturing firm that will enable it to scale up its technology platforms from Research/Pilot scale to commercial scale to help it achieve its mission.